-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s PT-101
Empower your strategies with our Net Present Value Model: Merck & Co Inc's PT-101 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
PT Bumi Resources Bengalon Complex, Indonesia
PT Bumi Resources Bengalon Complex is proposed to be built in East Kalimantan, Indonesia. Empower your strategies with our PT Bumi Resources Bengalon Complex, Indonesia report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-101 in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-101 in Vitiligo report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-101 in Vitiligo Drug Details: PT-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-886 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-886 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-886 in Gastric Cancer Drug Details: PT-886 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-101 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-101 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-101 in Ulcerative Colitis Drug Details: PT-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Prostate Cancer Drug Details: PT-217 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Cancer Drug Details: PT-217 is under development for the...
-
New
Likelihood of Approval and Phase Transition Success Rate Model – PT-150 in Alcohol Dependence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-150 in Alcohol Dependence report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-150 in Alcohol Dependence Drug Details: PT-150 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Carcinoma Drug Details: PT-217 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-101 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-101 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-101 in Systemic Lupus Erythematosus Drug Details: PT-101 is under development...